Akebia posts wider-than-expected Q4 net loss as higher expenses hurt

Reuters02-26
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt

Overview

  • Biopharmaceutical company's Q4 net income and operating income missed analyst expectations

  • Full-year net product revenues rose 49% over 2024, driven by Vafseo sales

  • Company expects significant Vafseo revenue growth in 2026 through expanded access

Outlook

  • Akebia expects significant Vafseo revenue growth in 2026 through expanded access and improved adherence

  • Company plans Phase 2 trial for AKB-097 in rare kidney diseases starting 2H 2026

  • Akebia expects Auryxia revenues to decrease in 2026 due to expanding generic competition

Result Drivers

  • EXPANDED ACCESS - Akebia expects significant Vafseo revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates

  • IMPROVED ADHERENCE - Improved patient adherence rates for Vafseo attributed to observed dosing protocols at dialysis centers

  • PIPELINE ADVANCEMENT - Enrollment underway for praliciguat Phase 2 trial in FSGS and AKB-097 Phase 2 trial planned for 2H 2026

Company press release: ID:nGNX3s05qs

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

Miss

-$12.24 mln

-$7.67 mln (3 Analysts)

Q4 Operating Income

Miss

-$8.55 mln

-$5.36 mln (4 Analysts)

Q4 Operating Expenses

$53.64 mln

Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy."

  • Wall Street's median 12-month price target for Akebia Therapeutics Inc is $4.00, about 230.6% above its February 25 closing price of $1.21

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment